Bopindolol (malonate)

Cat. No.: HY-B1562B

CAS No.: 82857-38-3

Molecular Formula: $C_{26}H_{32}N_2O_7$

Molecular Weight: 484.54

Target: Adrenergic Receptor; 5-HT Receptor; Renin

Pathway: GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Bopindolol ((±)-Bopindolol) malonate is an orally active antagonist of β-adrenoceptors (ARs) with partial agonist activity. Bopindolol malonate is non-selective for β1- and β2-ARs and has low affinity for β3-AR subtype. Bopindolol malonate has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Bopindolol malonate is a proagent of Pindolol (HY-B0982). Bopindolol malonate can be used for essential and renovascular hypertension research.
IC_{50} & Target	Adrenergic receptor, Renin, 5-HT receptors[1][4]
In Vivo	Bopindolol (intravenous injection; 8, 16 and 32 μg/kg) causes a dose-dependent inhibition of isoprenaline-induced tachycardia, and this agent is 4 times more potent than propranolol in anaesthetised dogs[1]. Bopindolol (0.3, 1 and 3 mg/kg; IP; single dosage) produces dose dependent decreases in diastolic blood pressure and in heart rate[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats (260-300 g)[2]
Dosage:	0.3, 1 and 3 mg/kg
Administration:	IP; single dosage
Result:	Produced dose dependent decreases in diastolic blood pressure, and the decrease of about 8 mmHg at 3 mg/kg. Decreased the heart rate in a dose-dependent manner.

REFERENCES

[1]. Harron DW, et al. Bopindolol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 1991 Jan;41(1):130-49.

[2]. H Tanaka, et al. Hypotensive effect of bopindolol in pithed rats. Gen Pharmacol. 1993 Mar;24(2):373-5.

[3]. Y Hosohata, et al. Bopindolol is a slowly dissociating beta 1-adrenoceptor antagonist when compared to other beta-blockers. Biol Pharm Bull. 1995 Aug;18(8):1066-71.

[4]. Nagatomo T, et al. Bopindolol: pharmacological basis and clinical implications. Cardiovasc Drug Rev. 2001 Spring;19(1):9-24.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA